The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer) or Lenvima / Kisplyx (Eisai), and Opdivo plus Cabometyx (Exelixis / Ipsen) have revolutionized the treatment of advanced and metastatic disease and are becoming stalwarts in the first-line setting. The expected approvals of triplet combinations incorporating immune checkpoint inhibitors and tyrosine kinase inhibitors will further diversify the first-line setting. During the forecast period, the anticipated entry of Orpathys (AstraZeneca) and zanzalintinib (Exelixis) will provide effective first-line options specifically for patients with non-clear-cell histologies. The adjuvant setting will experience the most growth in the RCC market, as a result of Keytruda’s label expansion and rapid adoption in the treatment of early-stage disease. Meanwhile, the approval of Welireg (Merck & Co.) is reshaping the treatment of Von Hippel-Lindau (VHL)-associated tumors, and the expected approvals of regimens containing this agent targeting all lines of treatment will further accelerate market growth.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.